Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 11/20 | 0.43 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 2/20 | 0.34 |
| ▸ | CCNC | P24863 | 1/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26311820 | 0.88 | GAK (0.40) | TBK1CDK8CCNCACVR1CHRM4 | |
| SCHEMBL25826720 | 0.86 | IRAK4 (0.38) | IRAK4TBK1 | |
| SCHEMBL23999704 | 0.84 | CDK8 (0.36) | IRAK4TBK1IDH1CDK8CCNC | |
| SCHEMBL25826716 | 0.82 | CCNC (0.51) | TBK1CDK8CCNCACVR1ATR | |
| SCHEMBL25826718 | 0.80 | IP6K1 (0.45) | IRAK4TBK1CDK8CCNC | |
| SCHEMBL25826717 | 0.80 | IP6K1 (0.48) | IRAK4CDK8CCNC | |
| SCHEMBL25820123 | 0.79 | ACVR1 (0.34) | IRAK4TBK1IDH1CDK8ACVR1 | |
| SCHEMBL25821244 | 0.79 | LRRK2 (0.43) | IRAK4 | |
| SCHEMBL24532876 | 0.75 | MAPT (0.41) | IDH1CDK8ACVR1RETKDR | |
| SCHEMBL26311818 | 0.74 | DOT1L (0.41) | CDK8CCNCACVR1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | IRAK4 1748/4885TBK1 824/4885IDH1 3108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.